Tryptophan metabolism: Entering the field of aging and age-related pathologies

Trends in Molecular Medicine

Volumn 19, Issue 6, 2013, Pages 336-344

  van der Goot, Annemieke T ^a   Nollen, Ellen A A ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

Age related diseases; Aging; Kynurenine pathway; Neurodegeneration; Protein homeostasis; TDO 2; Tryptophan

Indexed keywords

INDOLEAMINE 2,3 DIOXYGENASE; MAMMALIAN TARGET OF RAPAMYCIN; SOMATOMEDIN; TRANSCRIPTION FACTOR DAF 16; TRANSCRIPTION FACTOR FOXO; TRYPTOPHAN 2,3 DIOXYGENASE; TRYPTOPHAN;

ADAPTIVE IMMUNITY; AGING; ALZHEIMER DISEASE; ANGIOGENESIS; AUTOPHAGY; CELL PROLIFERATION; CELL STRESS; DIET RESTRICTION; ENERGY METABOLISM; ENERGY RESOURCE; FOOD INTAKE; HUMAN; HUNTINGTON CHOREA; IMMUNOCOMPETENT CELL; IMMUNOREGULATION; INNATE IMMUNITY; LIFE EXPECTANCY; LIFE EXTENSION; LIFESPAN; NERVE DEGENERATION; NONHUMAN; NUTRIENT AVAILABILITY; PHYSIOLOGICAL PROCESS; PROTEIN HOMEOSTASIS; PROTEIN SYNTHESIS; REPRODUCTION; REVIEW; TISSUE SPECIFICITY; TRYPTOPHAN METABOLISM; XENOBIOTIC METABOLISM; ANIMAL; METABOLISM; PATHOLOGY; SIGNAL TRANSDUCTION;

ANIMALIA;

AGING; ANIMALS; HUMANS; SIGNAL TRANSDUCTION; TRYPTOPHAN;

EID: 84878622154     PISSN: 14714914     EISSN: 1471499X     Source Type: Journal    
DOI: 10.1016/j.molmed.2013.02.007     Document Type: Review

References (92)

1. Scully T. Demography: To the limit. Nature 2012, 492:S2-S3.
2. Fontana L., et al. Extending healthy life span - from yeast to humans. Science 2010, 328:321-326.
3. Mair W., Dillin A. Aging and survival: the genetics of life span extension by dietary restriction. Annu. Rev. Biochem. 2008, 77:727-754.
4. Greer E.L., Brunet A. Different dietary restriction regimens extend lifespan by both independent and overlapping genetic pathways in C. elegans. Aging Cell 2009, 8:113-127.
5. Kenyon C.J. The genetics of ageing. Nature 2010, 464:504-512.
6. Wullschleger S., et al. TOR signaling in growth and metabolism. Cell 2006, 124:471-484.
7. Vellai T., et al. Genetics: influence of TOR kinase on lifespan in C. elegans. Nature 2003, 426:620.
8. Robida-Stubbs S., et al. TOR signaling and rapamycin influence longevity by regulating SKN-1/Nrf and DAF-16/FoxO. Cell Metab. 2012, 15:713-724.
9. Tullet J.M., et al. Direct inhibition of the longevity-promoting factor SKN-1 by insulin-like signaling in C. elegans. Cell 2008, 132:1025-1038.
10. Bjedov I., et al. Mechanisms of life span extension by rapamycin in the fruit fly Drosophila melanogaster. Cell Metab. 2010, 11:35-46.
11. Pinkston J.M., et al. Mutations that increase the life span of C. elegans inhibit tumor growth. Science 2006, 313:971-975.
12. Wu Y., et al. Circulating insulin-like growth factor-I levels regulate colon cancer growth and metastasis. Cancer Res. 2002, 62:1030-1035.
13. Morley J.F., et al. The threshold for polyglutamine-expansion protein aggregation and cellular toxicity is dynamic and influenced by aging in Caenorhabditis elegans. Proc. Natl. Acad. Sci. U.S.A. 2002, 99:10417-10422.
14. Cohen E., et al. Opposing activities protect against age-onset proteotoxicity. Science 2006, 313:1604-1610.
15. Killick R., et al. Deletion of Irs2 reduces amyloid deposition and rescues behavioural deficits in APP transgenic mice. Biochem. Biophys. Res. Commun. 2009, 386:257-262.
16. Freude S., et al. Neuronal IGF-1 resistance reduces Aβ accumulation and protects against premature death in a model of Alzheimer's disease. FASEB J. 2009, 23:3315-3324.
17. Cohen E., et al. Reduced IGF-1 signaling delays age-associated proteotoxicity in mice. Cell 2009, 139:1157-1169.
18. Anisimov V.N., et al. Rapamycin extends maximal lifespan in cancer-prone mice. Am. J. Pathol. 2010, 176:2092-2097.
19. Bove J., et al. Fighting neurodegeneration with rapamycin: mechanistic insights. Nat. Rev. Neurosci. 2011, 12:437-452.
20. Stone T.W., Darlington L.G. Endogenous kynurenines as targets for drug discovery and development. Nat. Rev. Drug Discov. 2002, 1:609-620.
21. van der Goot A.T., et al. Delaying aging and the aging-associated decline in protein homeostasis by inhibition of tryptophan degradation. Proc. Natl. Acad. Sci. U.S.A. 2012, 109:14912-14917.
22. Oxenkrug G.F. The extended life span of Drosophila melanogaster eye-color (white and vermilion) mutants with impaired formation of kynurenine. J. Neural Transm. 2010, 117:23-26.
23. Schroecksnadel S., et al. Influence of immunosuppressive agents on tryptophan degradation and neopterin production in human peripheral blood mononuclear cells. Transpl. Immunol. 2011, 25:119-123.
24. Kanai M., et al. Tryptophan 2,3-dioxygenase is a key modulator of physiological neurogenesis and anxiety-related behavior in mice. Mol. Brain 2009, 2:8.
25. Mellor A.L., et al. Cutting edge: induced indoleamine 2,3 dioxygenase expression in dendritic cell subsets suppresses T cell clonal expansion. J. Immunol. 2003, 171:1652-1655.
26. Frick B., et al. Increasing production of homocysteine and neopterin and degradation of tryptophan with older age. Clin. Biochem. 2004, 37:684-687.
27. Pertovaara M., et al. Indoleamine 2,3-dioxygenase activity in nonagenarians is markedly increased and predicts mortality. Mech. Ageing Dev. 2006, 127:497-499.
28. Friberg M., et al. Indoleamine 2,3-dioxygenase contributes to tumor cell evasion of T cell-mediated rejection. Int. J. Cancer 2002, 101:151-155.
29. Uyttenhove C., et al. Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase. Nat. Med. 2003, 9:1269-1274.
30. Muller A.J., et al. Inhibition of indoleamine 2,3-dioxygenase, an immunoregulatory target of the cancer suppression gene Bin1, potentiates cancer chemotherapy. Nat. Med. 2005, 11:312-319.
31. Pilotte L., et al. Reversal of tumoral immune resistance by inhibition of tryptophan 2,3-dioxygenase. Proc. Natl. Acad. Sci. U.S.A. 2012, 109:2497-2502.
32. Giorgini F., et al. A genomic screen in yeast implicates kynurenine 3-monooxygenase as a therapeutic target for Huntington disease. Nat. Genet. 2005, 37:526-531.
33. Campesan S., et al. The kynurenine pathway modulates neurodegeneration in a Drosophila model of Huntington's disease. Curr. Biol. 2011, 21:961-966.
34. Zwilling D., et al. Kynurenine 3-monooxygenase inhibition in blood ameliorates neurodegeneration. Cell 2011, 145:864-874.
35. Le Floc'h N., et al. Tryptophan metabolism, from nutrition to potential therapeutic applications. Amino Acids 2011, 41:1195-1205.
36. Yoshida R., et al. Induction of pulmonary indoleamine 2,3-dioxygenase by interferon. Proc. Natl. Acad. Sci. U.S.A. 1981, 78:129-132.
37. Hayaishi O., Yoshida R. Specific induction of pulmonary indoleamine 2,3-dioxygenase by bacterial lipopolysaccharide. Ciba Found. Symp. 1978, 65:199-203.
38. Guillemin G.J., et al. Kynurenine pathway metabolism in human astrocytes: a paradox for neuronal protection. J. Neurochem. 2001, 78:842-853.
39. Fukui S., et al. Blood-brain barrier transport of kynurenines: implications for brain synthesis and metabolism. J. Neurochem. 1991, 56:2007-2017.
40. Pfefferkorn E.R. Interferon γ blocks the growth of Toxoplasma gondii in human fibroblasts by inducing the host cells to degrade tryptophan. Proc. Natl. Acad. Sci. U.S.A. 1984, 81:908-912.
41. Gupta S.L., et al. Antiparasitic and antiproliferative effects of indoleamine 2,3-dioxygenase enzyme expression in human fibroblasts. Infect. Immun. 1994, 62:2277-2284.
42. MacKenzie C.R., et al. Growth inhibition of multiresistant enterococci by interferon-γ-activated human uro-epithelial cells. J. Med. Microbiol. 1999, 48:935-941.
43. Munn D.H., et al. Prevention of allogeneic fetal rejection by tryptophan catabolism. Science 1998, 281:1191-1193.
44. Mellor A.L., et al. Prevention of T cell-driven complement activation and inflammation by tryptophan catabolism during pregnancy. Nat. Immunol. 2001, 2:64-68.
45. Munn D.H., Mellor A.L. Indoleamine 2,3-dioxygenase and tumor-induced tolerance. J. Clin. Invest. 2007, 117:1147-1154.
46. Munn D.H., et al. Inhibition of T cell proliferation by macrophage tryptophan catabolism. J. Exp. Med. 1999, 189:1363-1372.
47. Lee G.K., et al. Tryptophan deprivation sensitizes activated T cells to apoptosis prior to cell division. Immunology 2002, 107:452-460.
48. Rohde J., et al. The TOR kinases link nutrient sensing to cell growth. J. Biol. Chem. 2001, 276:9583-9586.
49. Gao X., et al. Tsc tumour suppressor proteins antagonize amino-acid-TOR signalling. Nat. Cell Biol. 2002, 4:699-704.
50. Zhang P., et al. The GCN2 eIF2α kinase is required for adaptation to amino acid deprivation in mice. Mol. Cell. Biol. 2002, 22:6681-6688.
51. Harding H.P., et al. Regulated translation initiation controls stress-induced gene expression in mammalian cells. Mol. Cell 2000, 6:1099-1108.
52. Munn D.H., et al. GCN2 kinase in T cells mediates proliferative arrest and anergy induction in response to indoleamine 2,3-dioxygenase. Immunity 2005, 22:633-642.
53. Fallarino F., et al. The combined effects of tryptophan starvation and tryptophan catabolites down-regulate T cell receptor zeta-chain and induce a regulatory phenotype in naive T cells. J. Immunol. 2006, 176:6752-6761.
54. Fallarino F., et al. T cell apoptosis by tryptophan catabolism. Cell Death Differ. 2002, 9:1069-1077.
55. Frumento G., et al. Tryptophan-derived catabolites are responsible for inhibition of T and natural killer cell proliferation induced by indoleamine 2,3-dioxygenase. J. Exp. Med. 2002, 196:459-468.
56. Terness P., et al. Inhibition of allogeneic T cell proliferation by indoleamine 2,3-dioxygenase-expressing dendritic cells: mediation of suppression by tryptophan metabolites. J. Exp. Med. 2002, 196:447-457.
57. Wirleitner B., et al. Immune activation and degradation of tryptophan in coronary heart disease. Eur. J. Clin. Invest. 2003, 33:550-554.
58. Niinisalo P., et al. Indoleamine 2,3-dioxygenase activity associates with cardiovascular risk factors: the Health 2000 study. Scand. J. Clin. Lab. Invest. 2008, 68:767-770.
59. Pedersen E.R., et al. Systemic markers of interferon-γ-mediated immune activation and long-term prognosis in patients with stable coronary artery disease. Arterioscler. Thromb. Vasc. Biol. 2011, 31:698-704.
60. Lob S., et al. Inhibitors of indoleamine-2,3-dioxygenase for cancer therapy: can we see the wood for the trees?. Nat. Rev. Cancer 2009, 9:445-452.
61. Platten M., et al. Tryptophan catabolism in cancer: beyond IDO and tryptophan depletion. Cancer Res. 2012, 72:5435-5440.
62. Opitz C.A., et al. An endogenous tumour-promoting ligand of the human aryl hydrocarbon receptor. Nature 2011, 478:197-203.
63. Schwarcz R., et al. Kynurenines in the mammalian brain: when physiology meets pathology. Nat. Rev. Neurosci. 2012, 13:465-477.
64. Stone T.W., et al. An expanding range of targets for kynurenine metabolites of tryptophan. Trends Pharmacol. Sci. 2013, 34:136-143.
65. Savvateeva E., et al. Age-dependent memory loss, synaptic pathology and altered brain plasticity in the Drosophila mutant cardinal accumulating 3-hydroxykynurenine. J. Neural Transm. 2000, 107:581-601.
66. Widner B., et al. Degradation of tryptophan in neurodegenerative disorders. Adv. Exp. Med. Biol. 1999, 467:133-138.
67. Widner B., et al. Tryptophan degradation and immune activation in Alzheimer's disease. J. Neural Transm. 2000, 107:343-353.
68. Pearson S.J., Reynolds G.P. Increased brain concentrations of a neurotoxin, 3-hydroxykynurenine, in Huntington's disease. Neurosci. Lett. 1992, 144:199-201.
69. Guidetti P., et al. Early kynurenergic impairment in Huntington's disease and in a transgenic animal model. Neurosci. Lett. 2000, 283:233-235.
70. Guidetti P., et al. Elevated brain 3-hydroxykynurenine and quinolinate levels in Huntington disease mice. Neurobiol. Dis. 2006, 23:190-197.
71. van Ham T.J., et al. C. elegans model identifies genetic modifiers of α-synuclein inclusion formation during aging. PLoS Genet. 2008, 4:e1000027.
72. Kimura K.D., et al. daf-2, an insulin receptor-like gene that regulates longevity and diapause in Caenorhabditis elegans. Science 1997, 277:942-946.
73. Kenyon C., et al. A C. elegans mutant that lives twice as long as wild type. Nature 1993, 366:461-464.
74. Friedman D.B., Johnson T.E. A mutation in the age-1 gene in Caenorhabditis elegans lengthens life and reduces hermaphrodite fertility. Genetics 1988, 118:75-86.
75. Clancy D.J., et al. Extension of life-span by loss of CHICO, a Drosophila insulin receptor substrate protein. Science 2001, 292:104-106.
76. Tatar M., et al. A mutant Drosophila insulin receptor homolog that extends life-span and impairs neuroendocrine function. Science 2001, 292:107-110.
77. Holzenberger M., et al. IGF-1 receptor regulates lifespan and resistance to oxidative stress in mice. Nature 2003, 421:182-187.
78. Bluher M., et al. Extended longevity in mice lacking the insulin receptor in adipose tissue. Science 2003, 299:572-574.
79. Taguchi A., et al. Brain IRS2 signaling coordinates life span and nutrient homeostasis. Science 2007, 317:369-372.
80. Selman C., et al. Evidence for lifespan extension and delayed age-related biomarkers in insulin receptor substrate 1 null mice. FASEB J. 2008, 22:807-818.
81. Jia K., et al. The TOR pathway interacts with the insulin signaling pathway to regulate C. elegans larval development, metabolism and life span. Development 2004, 131:3897-3906.
82. Honjoh S., et al. Signalling through RHEB-1 mediates intermittent fasting-induced longevity in C. elegans. Nature 2009, 457:726-730.
83. Ravikumar B., et al. Inhibition of mTOR induces autophagy and reduces toxicity of polyglutamine expansions in fly and mouse models of Huntington disease. Nat. Genet. 2004, 36:585-595.
84. Khurana V., et al. TOR-mediated cell-cycle activation causes neurodegeneration in a Drosophila tauopathy model. Curr. Biol. 2006, 16:230-241.
85. Wang T., et al. TOR-mediated autophagy regulates cell death in Drosophila neurodegenerative disease. J. Cell Biol. 2009, 186:703-711.
86. Kapahi P., et al. Regulation of lifespan in Drosophila by modulation of genes in the TOR signaling pathway. Curr. Biol. 2004, 14:885-890.
87. Luong N., et al. Activated FOXO-mediated insulin resistance is blocked by reduction of TOR activity. Cell Metab. 2006, 4:133-142.
88. Spilman P., et al. Inhibition of mTOR by rapamycin abolishes cognitive deficits and reduces amyloid-β levels in a mouse model of Alzheimer's disease. PLoS ONE 2010, 5:e9979.
89. Harrison D.E., et al. Rapamycin fed late in life extends lifespan in genetically heterogeneous mice. Nature 2009, 460:392-395.
90. Miller R.A., et al. Rapamycin, but not resveratrol or simvastatin, extends life span of genetically heterogeneous mice. J. Gerontol. A: Biol. Sci. Med. Sci. 2011, 66:191-201.
91. Anisimov V.N., et al. Rapamycin increases lifespan and inhibits spontaneous tumorigenesis in inbred female mice. Cell Cycle 2011, 10:4230-4236.
92. Muller A.J., et al. Chronic inflammation that facilitates tumor progression creates local immune suppression by inducing indoleamine 2,3 dioxygenase. Proc. Natl. Acad. Sci. U.S.A. 2008, 105:17073-17078.